Objective-More than 70% of circulating homocysteine is disulfide-bonded to protein, but little is known about the specific proteins that bind homocysteine and their function as a consequence of homocysteine binding.
Methods and Results-When human plasma was incubated with [35 S]L-homocysteine, most of the homocysteine bound to albumin. However, additional homocysteine-binding proteins were detected, and 1 of them comigrated with fibronectin. Treatment with 2-mercaptoethanol removed the bound homocysteine, demonstrating the involvement of disulfide bonding. In contrast, [35 S]L-cysteine did not bind to fibronectin. Purified fibronectin bound Ϸ5 homocysteine molecules per fibronectin dimer. SDS-PAGE of a limited trypsin digestion of homocysteinylated fibronectin showed that several tryptic fragments contained [35 S]homocysteine. Sequence analysis demonstrated that the fragments containing bound homocysteine had localized mainly to the C-terminal region, within and adjacent to the fibrin-binding domain. Homocysteinylation of fibronectin significantly inhibited its capacity to bind fibrin by 62% (PϽ0.005). In contrast, neither the binding of fibronectin to gelatin nor its capacity to serve as an attachment factor for aortic smooth muscle cells was affected. Key Words: homocysteine Ⅲ fibronectin Ⅲ fibrin Ⅲ atherosclerosis Ⅲ thrombosis H omocysteine is a sulfhydryl-containing amino acid formed during the metabolism of methionine. In healthy well-nourished individuals, homocysteine metabolism is efficient and regulated, and the concentration of plasma total homocysteine is usually Յ12 mol/L. 1 Inborn errors of homocysteine metabolism, drugs that interfere with homocysteine metabolism, deficiencies of folic acid, vitamin B 6 or vitamin B 12 , and certain disease states, such as chronic renal failure, increase plasma total homocysteine levels. 2 The homocystinurias are a heterogeneous group of autosomal recessive diseases caused by inborn errors of homocysteine metabolism. [3][4][5] Patients with untreated homocystinuria have severe hyperhomocysteinemia (50 to 500 mol/L) and lifethreatening premature cardiovascular disease. Thrombosis, with or without embolism, is the major cause of death. Postmortem studies show multiple thrombotic occlusions and widespread premature atherosclerosis with intimal thickening. However, even mild hyperhomocysteinemia (15 to 25 mol/L), regardless of the underlying cause, is a strong independent risk factor for occlusive vascular disease, as shown by numerous case-control and prospective studies involving thousands of subjects. 1,2,6 The mechanisms of homocysteine-induced atherosclerosis and thrombosis have not been fully elucidated.
Conclusions-TheseIn normal individuals, Ͼ70% of circulating homocysteine is disulfide-bonded to plasma proteins. 7,8 The primary carrier of disulfide-bound homocysteine is albumin, 9 -12 but other proteins with accessible cysteine residues are also potential carriers. The binding of homocysteine to cysteine residues may disrupt normal protein structure and impair...